Our in vivo experiments demonstrated that cuproptosis increased the expression of E2-Ha—the mouse homolog of HLA-DRA, in tumor cells, and we found that the combination treatment resulted in significantly greater recruitment of CD4+T and CD8+T cells in tumor tissues when compared with anti-PD-1 treatment alone. Here, PDCD1 is linked to neoplasm.